Drug Pricing


  • Three people in suits sit on a dias at a Congressional hearing.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts

    Forced into testifying by Senate HELP chair Bernie Sanders, the heads of Bristol Myers Squibb, J&J and Merck largely avoided major missteps.

    By Feb. 8, 2024
  • An illustration of sickled red blood cells blocking a blood vessel.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    New CMS pilot to test payment scheme for pricey sickle cell gene therapies

    The agency is planning a pilot program across states to help sickle cell patients access treatments like the newly approved Casgevy and Lyfgenia.

    By Jan. 31, 2024
  • Trendline

    Biosimilars

    The arrival of lookalike competition to AbbVie’s Humira in the U.S. presents an opportunity, and a test, for the cost-saving potential of biosimilars.

    By BioPharma Dive staff
  • U.S. capitol building with stormy skies
    Image attribution tooltip
    Douglas Rissing via Getty Images
    Image attribution tooltip

    Sanders threatens to subpoena J&J, Merck CEOs over drug prices

    The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.

    By Jan. 19, 2024
  • A photograph of the exterior of the Food and Drug Administration headquarters in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA authorizes Florida to import drugs from Canada

    The clearance is a major shift for the agency, which described its decision as a “first step” in allowing Florida to bulk purchase lower-cost Canadian medicines. 

    By , Jan. 5, 2024
  • drug pricing protest
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Humira leads ICER’s latest list of ‘unsupported’ price hikes

    AbbVie’s blockbuster medicine topped a list of treatments that, combined, elevated U.S. healthcare spending by $1.3 billion in 2022, according to the price watchdog’s latest yearly report.

    By Dec. 11, 2023
  • An illustration of sickled red blood cells.
    Image attribution tooltip
    EzumeImages via Getty Images
    Image attribution tooltip

    Pricey new gene therapies for sickle cell pose access test

    Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2 million, while Bluebird’s competing genetic medicine is priced at $3.1 million.

    By Dec. 8, 2023
  • U.S. President Joe Biden gestures with his hands while speaking from behind a podium.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Biden administration goes after drug patents in bid to lower prices

    The White House is supporting a policy that would allow the U.S. government to sidestep patent protections for drugs developed with federal funding and that have prices deemed “extreme, unjustified, and exploitative.”

    By Dec. 7, 2023
  • A window with the logo for Amicus Therapeutics.
    Image attribution tooltip
    Amicus Therapeutics
    Image attribution tooltip

    BIO names longtime Amicus head John Crowley as new CEO

    Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.

    By Dec. 5, 2023
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin secures hemophilia gene therapy coverage in Germany

    Drawn-out negotiations led to a lower price than initially expected, but analysts called the agreement a step forward for the biotech company.

    By Kristin Jensen • Nov. 29, 2023
  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images
    Image attribution tooltip

    FTC challenges patents held by nine big drugmakers, citing unfair competition

    The agency claims intellectual property for emergency allergy shot EpiPen and asthma medication Advair was “improperly listed” in an FDA database.

    By Nov. 8, 2023
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Biogen, Sage set price of postpartum depression pill at $15,900

    The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.

    By Nov. 7, 2023
  • Congressman Garcia gestures to a cardboard meme of two identical Spiderman characters pointing at one another.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    PBMs, PhRMA trade blame over drug costs in House hearing

    Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.

    By Rebecca Pifer • Sept. 19, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Astellas withdraws lawsuit challenging Medicare drug price program

    The drugmaker said it still believes the U.S. government’s price negotiation powers are unconstitutional, but is pulling back a lawsuit it filed in July.

    By Sept. 7, 2023
  • Joe Biden stands at a podium flanked on either sides by screens that read: "lowering costs for American families."
    Image attribution tooltip
    Win McNamee / Staff via Getty Images
    Image attribution tooltip

    Medicare named the first 10 drugs up for negotiation. Now what?

    The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

    By Karissa Waddick • Aug. 30, 2023
  • U.S. President Joe Biden gestures with his hands while speaking from behind a podium.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Medicare names first 10 drugs for price negotiations

    The Inflation Reduction Act gave the U.S. government new pricing powers, which CMS put into practice this August with its first slate of blockbuster targets.

    By Updated Aug. 29, 2023
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca the latest pharma to challenge drug pricing law

    The drugmaker's lawsuit follows similar legal challenges from Merck & Co., Bristol Myers Squibb and Johnson & Johnson, among others. 

    By Aug. 25, 2023
  • A view from below of the CVS sign on the center of a building, with a vertical blue HealthHub sign to its right.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    CVS launches new venture in biosimilar drug experiment

    The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

    By Aug. 24, 2023
  • Boehringer sues to block US drug price program

    The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.

    By Aug. 22, 2023
  • A picture of the exterior of a CVS Pharmacy with the logo and name in view.
    Image attribution tooltip
    Bruce Bennett via Getty Images
    Image attribution tooltip

    Blue Shield of California drops CVS Caremark in pharmacy benefit overhaul

    BSCA has kicked CVS Caremark, the largest pharmacy benefit manager in the country, to the curb and is electing to carve out various pharmacy functions with companies like Amazon instead.

    By Rebecca Pifer • Updated Aug. 17, 2023
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx
    Image attribution tooltip

    EQRx to sell to Revolution Medicines after failed bid to upend US drug pricing

    The all-stock deal is a quiet end for the ambitious biotech, which was sold for its billion-dollar bank account after the FDA derailed its plans to develop low-cost cancer medicines.

    By Aug. 1, 2023
  • A office building is seen with a sign reading "GlaxoSmithKline."
    Image attribution tooltip
    Leon Neal via Getty Images
    Image attribution tooltip
    RSV vaccines

    GSK confident in RSV vaccine launch, but sets expectations for ‘steady build’

    GSK expects its respiratory syncytial virus vaccine will be a multibillion dollar product. But at the beginning, it’s predicting a slower launch than for its fast-selling shingles shot.

    By July 27, 2023
  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip
    Patent thickets

    Biosimilar makers split strategies in bid to take on top-selling Humira

    In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

    By July 26, 2023
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J joins pharma allies in challenging US drug pricing law

    The pharma claimed in federal court that the Inflation Reduction Act, which threatens sales of its blood thinner Xarelto, amounts to “confiscation of constitutionally protected property.”

    By Kristin Jensen • July 19, 2023
  • The U.S. Supreme Court is seen in spring through the branches of a tree.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Pharma’s strike-from-all-sides attack on the IRA could end up at the Supreme Court

    Industry lawsuits have taken a ‘multi-pronged’ approach to challenge the Inflation Reduction Act’s price negotiation program on constitutional grounds. 

    By Alexandra Pecci • July 6, 2023
  • A photograph of the exterior of the Food and Drug Administration headquarters in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Alvotech to raise cash after third FDA rejection for Humira biosimilar

    The latest regulatory setback, tied to continuing manufacturing issues, ensures Alvotech and partner Teva won’t be able to launch their drug alongside a wave of emerging Humira copycats.  

    By Kristin Jensen • June 29, 2023